Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Unravelling the interaction mechanism between clioquinol and bovine serum albumin by multi-spectroscopic and molecular docking approaches
Graphical abstract
Introduction
Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline, Fig. 1) is a member of hydroxyquinoline family and commercially available in cream preparation for treatment of inflammatory skin disorders such as eczema, ringworm, and athlete's foot. The previous study demonstrated that clioquinol exerts high antimicrobial activity against the multidrug resistant Neisseria gonorrhoeae [1]. In addition, clioquinol was also reported to exhibit anticancer activity toward cholangiocarcinoma cells [2] and displayed neuroprotective effects against high glucose toxicity [3]. Currently, clioquinol and hydroxyquinoline derivatives have been proposed for treatment of neurodegenerative disorders including Alzheimer's, Huntington's, and Parkinson's diseases [4]. In this context, clioquinol plays many key roles in the brain including reduction of beta-amyloid burden, restoration of metal homeostasis, and improvement of cognition. It acts as a metal chelator toward Cu and Zn, which in turn depletes β-amyloid protein aggregation [[5], [6], [7], [8], [9], [10], [11], [12]] and restores cognition of transgenic Alzheimer's mice [8,[13], [14], [15]]. Unfortunately, adverse effects of clioquinol have been noted. Because of its association with subacute myelo-optic neuropathy (SMON); thus, oral clioquinol has been terminated since the 1970s [16,17]. The mechanism of such toxicity still remains unclear. It is believed that clioquinol reduces vitamin B12 bioavailability resulting in sensory and motor disorders of the lower limbs and the visual sign [[18], [19], [20]]. It also inhibits 20s proteasome and leads to misfolded protein aggregation and cell death [21]. Sampson and colleagues have mentioned that clinical trial of clioquinol for treatment of Alzheimer's participants showed no statistically significant difference among the active treatment and the placebo groups. However, one participant in the clioquinol-treated group developed neurological symptoms [22,23]. Therefore, the planned phase III trial of clioquinol had been terminated [23].
Owing to a controversy in balancing the clinical benefits and the side effects of clioquinol, further explorations in several aspects are still needed to be elucidated, for examples protein-drug interaction, pharmacokinetics, pharmacodynamics, pharmacological effects, and toxicity studies. Clioquinol undergoes first-pass metabolism to form glucuronide and sulfate conjugates. In human, clioquinol is less metabolized than that in rodents, and its half-life is about 10–14 h [24]. The serum level of clioquinol has been found in a range of 13–25 μM after orally administered to Alzheimer's disease patient [22]. Furthermore, several lines of evidence have revealed that the higher accumulation of clioquinol may exert more toxicity to human [17,25,26]. Interaction of drug with serum protein is one of the major factors that influence on half-life and free drug concentrations in the blood stream. Serum albumin is an abundant protein in circulatory system of mammal. It is responsible for many functions in our body, especially storing and transporting various endogenous and exogenous compounds, controlling physiological pH, and maintaining oncotic pressure. In some circumstances, binding of drug with serum albumin may enhance its transportation to drug target or vice versa. Bovine serum albumin (BSA) is typically exploited as a representative of serum proteins for in vitro study of protein-drug interaction because of its low cost, structural similarity to human serum albumin (HSA), and easy accessibility [27]. BSA is a globular non-glycoprotein comprising of 583 amino acids on a single polypeptide chain. Its structure can be categorized into three homologous domains including I (residue 1–195), II (residue 196–383), and III (residue 384–583) domains, where each domain contains sub-domains A and B. The hydrophobic pockets in subdomains IIA and IIIA, respectively named as site I and site II, have been identified as the binding sites for aromatic and heterocyclic compounds [28,29]. The third binding pocket within subdomain IB (site III) has recently been identified as the primary binding site for many compounds e.g. bilirubin, hemin, and sulfonamide derivatives. Seven binding sites for fatty acids have been recognized on subdomains IB, IIIA, IIIB, and subdomain interfaces [29,30]. BSA contains two tryptophan residues located on the surface of subdomain IA (Trp-134) and in the hydrophobic pocket of subdomain IIB (Trp-212), in which it can be employed as intrinsic fluorescence indicators for probing the BSA-ligand interaction.
Although there is extensive consideration of clioquinol repositioning for anti-Alzheimer's and anti-cancer drugs, the information about its interaction with serum proteins is rarely available and remains a challenge for elucidation. Therefore, this study aims to explore the interaction between clioquinol and serum albumin by using BSA as a representative. To postulate the interaction mechanism and the binding parameters, we exploited various mathematic models on the fluorescence quenching data, especially Stern-Volmer's, Hill's, and thermodynamic equations. Besides, molecular docking was also taken to explore structural information of the BSA-clioquinol interaction, including the favored binding site, the preferred orientation, and the binding energy.
Section snippets
Materials
Bovine serum albumin (BSA; >98% purity with essentially fatty acid free), clioquinol, warfarin, ibuprofen, and digitoxin were purchased from Sigma-Aldrich Co. LLC. (St. Louise, MO, USA). Other chemicals were analytical grade and used without further purification. BSA was dissolved in Tris-HCl (10 mM Tris-HCl, 150 mM NaCl, pH 7.4) and determined its concentration by absorbance measurement at 280 nm with an extinction coefficient of 36,500 M−1 cm−1. Clioquinol was dissolved in methanol and kept
Effect of clioquinol on absorption spectra of BSA
Careful analysis of the absorption spectra can help to distinguish the mechanism of interaction between protein and ligand. Collisional quenching affects the excited state of the fluorophore, in which no change of the absorption spectra could be observed. In contrast, ground-state complex formation frequently alters the absorption spectra of the fluorophore. Herein, BSA exhibited a major absorption peak at ~280 nm, which was correspondence with the absorption characteristic of tryptophan (Trp)
Conclusion
In this study, the molecular interaction between clioquinol and BSA was explored using the combination of multi-spectroscopic and computational approaches. Spectroscopic results imply that clioquinol interacts with BSA via both static and dynamic processes. The binding constant of the BSA-clioquinol complex is extremely high at 108 M−1 level, which is well comparable to previous report about the binding of clioquinol to human serum albumin at partition equilibrium between aqueous and oil [8,41
Acknowledgements
This project is supported by the Faculty of Medical Technology, Mahidol University and the Office of the Higher Education Commission and Mahidol University under the National Research Universities Initiative (B.E. 2557-2558). Thankfulness is extended to Asst. Prof. Dr. Kamonrat Phopin and Miss Walaree Ruankham for their kind assistances and support some chemicals.
References (50)
- et al.
Amyloid β-interacting partners in Alzheimer's disease: from accomplices to possible therapeutic targets
Prog. Neurobiol.
(2016) - et al.
A molecular approach in drug development for Alzheimer's disease
Biomed. Pharmacother.
(2018) - et al.
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease
Eur. J. Med. Chem.
(2019) The metallobiology of Alzheimer's disease
Trends Neurosci.
(2003)- et al.
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta
Neuron.
(2008) - et al.
Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies
Prog. Neurobiol.
(2019) - et al.
Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice
Neuron.
(2001) - et al.
Changes in uptake of vitamin B12 and trace metals in brains of mice treated with clioquinol
J. Neurol. Sci.
(2000) - et al.
The toxicology of Clioquinol
Toxicol. Lett.
(2008) - et al.
Pharmacokinetics of iodochlorhydroxyquin in man
J. Pharm. Sci.
(1973)
Elucidation of intermolecular interaction of bovine serum albumin with fenhexamid: a biophysical prospect
J. Photochem. Photobiol. B
Spectroscopic studies on the interaction between methylene blue and bovine serum albumin
J. Photoch. Photobio. A
Fluorescence spectral resolution of tryptophan residues in bovine and human serum albumins
J. Pharm. Biomed. Anal.
Study on the binding of chloroamphenicol with bovine serum albumin by fluorescence and UV-vis spectroscopy
Spectrochim. Acta A Mol. Biomol. Spectrosc.
Fluorescence quenching studies with proteins
Anal. Biochem.
In vitro study on the binding of gemcitabine to bovine serum albumin
J. Pharm. Biomed. Anal.
Spectroscopic investigations on the mechanism of interaction of bioactive dye with bovine serum albumin
Dyes Pigments
Spectral characterization of the binding and conformational changes of bovine serum albumin upon interaction with an anti-fungal drug, methylparaben
Spectrochim. Acta A Mol. Biomol. Spectrosc.
A comparison study on the interaction of hyperoside and bovine serum albumin with Tachiya model and Stern-Volmer equation
Spectrochim. Acta A Mol. Biomol. Spectrosc.
Spectroscopic analysis on the binding interaction of biologically active pyrimidine derivative with bovine serum albumin
J. Pharm. Anal.
Molecular basis of the inhibition and disaggregation of thermally-induced amyloid fibrils of human serum albumin by an anti-Parkinson's drug, benserazide hydrochloride
J. Mol. Liq.
The complexity of condensed tannin binding to bovine serum albumin – An isothermal titration calorimetry study
Food Chem.
Repositioning of 8-hydroxyquinoline derivatives as a new promising candidate for combating multidrug resistant Neisseria gonorrhoeae
EXCLI J.
Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells
Drug. Des. Devel. Ther.
Effect of 8-hydroxyquinoline and derivatives on human neuroblastoma SH-SY5Y cells under high glucose
PeerJ
Cited by (43)
Effects of polystyrene nanoplastics on the binding of ciprofloxacin to bovine serum albumin
2024, Colloids and Surfaces A: Physicochemical and Engineering AspectsSpectroscopy and molecular simulation on the interaction of Nano-Kaempferol prepared by oil-in-water with two carrier proteins: An investigation of protein–protein interaction
2024, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyInteraction mechanism of a pesticide, Azoxystrobin with bovine serum albumin: Assessments through fluorescence, UV–Vis absorption, electrochemical and molecular docking simulation techniques
2024, Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy